PEMBROLIZUMAB

108520 reported adverse events

Drug classes: Programmed Death Receptor-1 Blocking Antibody [EPC]

These side effects are most commonly reported by patients taking PEMBROLIZUMAB:

# Side effect Count
0 MALIGNANT NEOPLASM PROGRESSION 12384
1 DEATH 6043
2 DIARRHOEA 5920
3 FATIGUE 5236
4 OFF LABEL USE 4866
5 PYREXIA 4018
6 RASH 3883
7 NAUSEA 3672
8 PRODUCT USE IN UNAPPROVED INDICATION 3594
9 DECREASED APPETITE 3399
See all common reactions for PEMBROLIZUMAB

PEMBROLIZUMAB is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 IMMUNE-MEDIATED HYPOTHYROIDISM 701 0.6215
1 IMMUNE-MEDIATED RENAL DISORDER 257 0.6208
2 IMMUNE-MEDIATED HYPERTHYROIDISM 156 0.6142
3 IMMUNE-MEDIATED ADRENAL INSUFFICIENCY 477 0.5985
4 IMMUNE-MEDIATED ADVERSE REACTION 893 0.5814
5 IMMUNE-MEDIATED HEPATIC DISORDER 1047 0.5364
6 IMMUNE-MEDIATED THYROIDITIS 263 0.5324
7 IMMUNE-MEDIATED PANCREATITIS 189 0.4961
8 IMMUNE-MEDIATED ARTHRITIS 187 0.4908
9 IMMUNE-MEDIATED MYOCARDITIS 779 0.4821
See all enriched reactions for PEMBROLIZUMAB